CCM
NVAX icon

Cadence Capital Management’s Novavax NVAX Stock Holding History

Cadence Capital Management’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-8,910
Closed -$823K – 581
2014
Q2 		$823K Buy
8,910
+3,259
+58% +$286K 0.04% 435
2014
Q1 		$512K Buy
+5,651
New +$631K 0.02% 516

Other funds holding NVAX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Cadence Capital Management's NVAX Position: Q3 2014 in Review

Cadence Capital Management sold out of Novavax (NVAX) in Q3 2014, closing a stake of 8,910 shares — an estimated $823K sold.

Cadence Capital Management first reported a position in NVAX in Q1 2014 and held it in 2 quarters. The position peaked at $823K in Q2 2014. 143 funds tracked by Wall St. Rank hold NVAX as of Q3 2014.

  • Cadence Capital Management reported no remaining Novavax position as of Q3 2014 after selling out during the quarter.
  • Cadence Capital Management sold 8,910 Novavax shares in Q3 2014, an estimated $823K.
  • Cadence Capital Management first reported a position in Novavax in Q1 2014 and held it in 2 quarters.
  • Cadence Capital Management's Novavax position peaked at $823K in Q2 2014.
  • 143 funds tracked by Wall St. Rank held Novavax as of Q3 2014.

Based on Cadence Capital Management's 13F filing for Q3 2014, filed 3 Nov 2014.